PF-Atlas › Clinical Trials › NCT05954988
A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis Patients
LTI-03 · Phase 1
Registry ID
NCT05954988
Phase
Phase 1
Status
Completed
Drug / intervention
LTI-03
Sponsor
Rein Therapeutics
Start
2023-07-06
Enrollment
24
Locations
7
About this trial
This study will assess the safety and tolerability of inhaled LTI-03 in treatment naïve participants with newly diagnosed IPF.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT05954988 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.